DESIGN PRINCIPLES FOR MAXIMIZING THE DRUG DELIVERY EFFICIENCY AND THERAPEUTIC INDEX OF ADCS
Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd.
The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues.
This phenomenon has two potential negative consequences—unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC.
Careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor.
Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and we are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma.
SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018. The Antibody-drug Conjugates market is expected to reach USD 30 Billion by 2023*. http://bit.ly/2hxLtOS
Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.
Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.
Hear from some of the best minds in the industry and partake in valuable discussion with key leaders within the field at this topical and timely event!